JavaScript is disabled for your browser. Some features of this site may not work without it.
Statistics
Total Visits
| Views | |
|---|---|
| Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial | 130 |
Total Visits Per Month
| June 2024 | July 2024 | August 2024 | September 2024 | October 2024 | November 2024 | December 2024 | |
|---|---|---|---|---|---|---|---|
| Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial | 6 | 2 | 10 | 6 | 5 | 4 | 5 |
Top country views
| Views |
|---|
Top cities views
| Views |
|---|
